Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy

@article{Holgate2005AntiimmunoglobulinET,
  title={Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy},
  author={Stephen T Holgate and Ratko Djukanovi{\'c} and Thomas B. Casale and Jean Bousquet},
  journal={Clinical \& Experimental Allergy},
  year={2005},
  volume={35}
}
Omalizumab is a humanized monoclonal anti‐IgE antibody developed for the treatment of allergic disease, with established efficacy in patients with moderate‐to‐severe allergic asthma and in patients with intermittent (seasonal) and persistent (perennial) allergic rhinitis (AR). Omalizumab is known to result in a marked reduction in serum levels of free IgE and down‐regulation of IgE receptors on circulating basophils. Recent work has shed further light on its mechanism of action, showing… 

Current and future applications of the anti-IgE antibody omalizumab

There are data indicating the usefulness of omalizumab when used in combination with allergen specific immunotherapy, in terms of reducing the adverse reactions to treatment and increasing the clinical efficacy.

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Omalizumab effectively blunts the immune response in atopic asthmatic patients, thus significantly improving the control of asthma symptoms and successfully preventing disease exacerbations.

Update on optimal use of omalizumab in management of asthma

Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions, therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.

The discovery and development of omalizumab for the treatment of asthma

While omalizumab is the only mAb available for treating allergic asthma, the authors anticipate that new mAbs will emerge in the future that overcome omalIZumab’s current limitations.

Anti-IgE as a mast cell-stabilizing therapeutic agent.

  • T. ChangY. Shiung
  • Biology, Medicine
    The Journal of allergy and clinical immunology
  • 2006

The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis

  • R. Moss
  • Biology, Medicine
    Annals of the New York Academy of Sciences
  • 2012
Omalizumab, a humanized monoclonal antibody, targets the same epitope on the IgE CH3 region that binds to and crosslinks high‐affinity receptors on mast cells and basophils, thereby initiating the allergic inflammatory cascade.

Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis

Omalizumab therapy reduced the need for systemic corticosteroid bursts and improved effectiveness of asthma treatment as judged by both physicians and patients.

The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response

Omalizumab treatment can also be used in patients with immunoglobulin deficiency, and a significant reduction was found in neutrophil counts after the treatment, whereas there was no significant difference in eosinophil, lymphocyte and platelet levels.

Altered immunoglobulin E diversity and regulation of allergic inflammation in asthma

  • J. Davies
  • Medicine, Biology
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2009
Increased knowledge of how IgE exerts its effects will underpin effective clinical use of anti-IgE treatment and investigate the effects of altered antibo dy repertoire on the outcomes of an experimental model of allergic asthma.
...

References

SHOWING 1-10 OF 55 REFERENCES

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

The lack of effect of omalizumab on methacholine responsiveness suggests that IgE or eosinophils may not be causally linked to airway hyperresponsiveness to Methacholine in mild to moderate asthma.

The effect of omalizumab on nasal allergic inflammation.

The clinical benefit of treatment with omalizumab is associated with an anti-inflammatory effect on cellular markers in blood and nasal tissue.

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.

  • P. ChervinskyT. Casale H. Fox
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2003

Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality*

In patients at high risk of serious asthma-related morbidity and mortality, treatment with omalizumab offers the potential to halve the rate of asthma exacerbations and improve disease control.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Omalizumab has been reported to be safe and effective in improving asthma control and reducing the requirement for oral and inhaled corticosteroids, and cause a down-regulation of FcepsilonRI receptors on basophils.

Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab

It is suggested that omalizumab has potential as a novel treatment for allergic asthma and circulating levels of inflammatory mediators and clinical symptoms in patients with moderate to severe allergic asthma decreased.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use.

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

A recombinant humanized monoclonal antibody directed against IgE has potential as a treatment for subjects with moderate or severe allergic asthma and was well tolerated.

Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

The aim of this study was to evaluate the efficacy and safety of omalizumab in patients with concomitant moderate‐to‐severe asthma and persistent allergic rhinitis.
...